TAVR for Low-Risk Patients to be Discussed at STS/ACC Session

Vinod H. Thourani, MD

The potential for transcatheter aortic valve replacement (TAVR) in low-risk patients is quickly becoming a hot topic for cardiothoracic surgeons and cardiologists. The issue will be debated during a joint STS and American College of Cardiology session at the STS 52nd Annual Meeting. STS Past President Michael J. Mack, MD will go head-to-head with ACC Past President David R. Holmes Jr., MD on this timely topic.

“Right now, TAVR can be performed safely and effectively on medium- and high-risk patients. Some are now questioning the use of TAVR for low-risk patients,” said Vinod H. Thourani, MD, co-moderator of ACC @ STS, which will be presented from 1:15 p.m. to 4:30 p.m. on Sunday, January 24. “Quite honestly, surgeons are concerned that the management of aortic stenosis may leave the decision-making of surgeons in the hands of cardiologists. The question remains: What role will surgeons have? This debate, by two icons in our specialty, is not to be missed.”

The session also will illustrate the importance of the heart team in the management of patients with aortic valve disease, coronary artery disease, and mitral regurgitation.

“We see these patients on a daily basis, and they can do well through the coordinated efforts of a cardiovascular team—a true heart team approach—instead of with a surgeon or cardiologist alone,” said Dr. Thourani, Professor of Surgery and Medicine at Emory University School of Medicine, Co-Director of the Structural Heart and Valve Center at the Emory Heart and Vascular Center, and Chief of Cardiothoracic Surgery at Emory University Hospital Midtown in Atlanta.

Throughout the session, some of the world’s most well-known and thoughtful cardiothoracic surgeons and cardiologists will share their insights, technical videos, literature reviews, data-driven guidelines, and case examples.

An update on research from the STS/ACC Transcatheter Valve Therapy (TVT) RegistryTM will be provided. The TVT Registry is releasing its baseline outcomes report in The Annals of Thoracic Surgery.

A follow-up report on the National Institutes of Health Cardiothoracic Surgical Trials Network Moderate and Severe Ischemic Mitral Regurgitation Trials also will be featured. Michael A. Acker, MD will explain how to best manage these patients, based on the results of these highly contested and controversial trials.

“Surgeons continue to struggle with the appropriate therapy for replacement in patients with severe ischemic mitral regurgitation or coronary bypass alone for those with moderate ischemic mitral regurgitation,” Dr. Thourani said. “The entire ACC @ STS session is unique in that attendees will learn about some of the most perplexing, yet commonly encountered patient situations from world-class cardiologists and surgeons alike.”

Top